-
2023-504263-16-00
5
2023-05-25
This is an extension study designed to provide continued treatment for
-
2024-513669-38-00
5
2023-05-17
Stroke, Ischemic, TIA, Cardiac Disease, Atherosclerosis, Myocardial In
-
2023-506716-41-00
9
2023-05-08
Adult patients with advanced (metastatic or unresectable) KRAS G12C
mu
-
2024-514636-25-00
4
2023-05-04
Stage IIa/IIb < 3 cm seminoma
-
2022-501124-23-00
5
2023-04-18
General anesthesia and sedative and anxiolytic sedation
-
2023-504897-39-00
1
2023-04-13
Advanced or refractory solid tumours (Part 1)
-
2023-505040-19-00
4
2023-04-11
Non-seminomatous germ-cell tumors (including testis, retroperitoneal a
-
2022-501494-39-00
5
2023-03-28
Uncontrolled Hypertension IN patients with moderate to severe chronic
-
2022-501636-42-00
9
2023-03-21
Advanced RET-altered malignancies
-
2024-513578-23-00
4
2023-03-21
Tumors harboring BRAF alterations
-
2023-507233-19-00
10
2023-02-16
Treatment of IgAN
-
2024-517414-15-00
4
2023-01-25
ER positive HER2 negative breast cancer
-
2024-514913-37-00
11
2023-01-12
Respiratory distress
-
2023-504885-50-00
5
2022-11-07
Treatment of children with chronic kidney disease and proteinuria
-
2023-504264-41-00
9
2022-11-04
CD20 positive B-Cell Non-Hodgkin Lymphoma (NHL)
-
2022-500264-35-00
1
2022-10-28
Advanced solid tumor with a PIK3CA mutation in blood and/or tumor per
-
2023-508425-28-00
4
2022-10-24
Chronic Inflammatory Demyelinating Polyneuropathy
-
2023-508129-28-00
9
2022-09-28
Pediatric patients with Philadelphia chromosome positive chronic myelo
-
2024-513327-16-00
5
2022-09-20
Intensive care
-
2022-502687-20-00
4
2022-09-14
Wilms tumor
-
2023-507557-16-00
5
2022-08-31
chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
-
2024-511899-32-00
10
2022-08-31
Dermatomyositis; Baricitinib in patients with relapsing or naïve derma
-
2024-515243-37-00
11
2022-08-21
Kidney Transplantation
BKV infection
-
2024-512822-28-00
1
2022-08-08
Advanced or metastatic solid tumors